# Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

> **NCT02660359** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 258 (actual)

## Conditions studied

- Urinary Incontinence
- Overactive Bladder

## Interventions

- **BIOLOGICAL:** Botulinum toxin type A
- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02660359
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-08
- **Primary completion:** 2018-11-09
- **Final completion:** 2019-07-04
- **Target enrollment:** 258 (ACTUAL)
- **Why stopped:** Slow recruitment of patients
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660359, "Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02660359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*